Ami Organics Limited
CIN No. : L24100GJ2007PLC051093
Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

April 29, 2022

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot no. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

NSE Symbol: AMIORG

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release dated April 29, 2022.

This Press Release will also be available on the website of the Company www.amiorganics.com

Kindly take the same on record.

Yours faithfully,
For, AMI ORGANICS LIMITED

Ekta Kumari

Ekta Kumari Srivastava
Company Secretary & Compliance Officer

AMI ORGANICS LTD. * SACHIN *

Encl: As Above

Info@amiorganics.com www.amiorganics.com +91 72279 77744 / 75730 15366

PRESS RELEASE
For Immediate dissemination

AMI ORGANICS LIMITED

Ami Organics to Expand Capacity through Brownfield Plant at Ankleshwar

Board of Directors approves Capex of INR 190 crores

Surat, April 29, 2022: Ami Organics Limited (AMI) (BSE: 543349), NSE: AMIORG) today announced that the board of directors of the company has approved the Capex plan of **INR 190cr** to build a brownfield plant in Ankleshwar, Gujarat, to support the future business growth in the company's advanced pharmaceutical intermediates segment.

Ami Organics acquired two facilities at Ankleshwar and Jhagadia from the Gujarat Organics on 31st March 2021. The production at the Ankleshwar unit was successfully transferred to the Jhagadia unit during the last quarter for optimum utilisation of resources without losing any revenue. Currently, the old plant at Ankleshwar is being demolished and the new plant will be built on this site.

The Ankleshwar site has received necessary environmental clearance and the new facility will have ~90 reactors taking the total reactor capacity to 436KL. The plant is expected to start commercial operations from Q4FY24. The Capex will be funded through a mix of General Corporate funds of IPO proceeds, internal accruals, and debt. Currently, the company does not have long-term debt on the books other than a short-term working capital loan.

The current capacity utilisation at the Sachin unit in Surat, Gujarat which manufactures the majority of the pharmaceutical intermediates is at ~65%.

Commenting on the Capex plan, Mr. Nareshkumar Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: *"We envisage an increase in demand for our existing products as well as for our products in the pipeline. The CAPEX that we have planned will help us cater to this growing demand till 2027-28.*

*Our plant at Sachin is running at a capacity of around ~65%. To ensure that we have enough capacity to cater to the growing demand until the new project at Ankleshwar is complete, we are in the process of shifting some of our existing as well as new products to "**continuous flow reactors"**. This will help free up a considerable capacity at the Sachin unit. It gives me immense pleasure to share that we have successfully shifted the manufacturing of two products from the traditional method to **"continuous flow reactors".***

We will continue to invest in improving our processes and strategically shift high volume products to advanced technology that will allow our business to stay sustainable and maintain our margins given the uncertain external global environment and supply-chain challenges."

AMI ORGANICS LIMITED

ABOUT AMI ORGANICS LIMITED:

Headquartered in Surat, Ami Organics is an R&D-driven manufacturer of specialty chemicals with varied end usage. The Company is focused on the development and manufacturing of advanced pharmaceutical intermediates ("Pharma Intermediates") for regulated markets and generic active pharmaceutical ingredients ("APIs") and New Chemical Entities ("NCE") and key starting materials for agrochemical and fine chemicals. AMI has developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at AMI Organics	Registered Office
Ekta Srivastava, Company Secretary & Compliance Officer cs@amiorganics.com **Ernst & Young LLP** Mr. Rahul Thakur Rahul.Thakur@in.ey.com	Plot no. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01017 NSE Code: AMIORG BSE CODE: 543349 Website: www.amiorganics.com